Medicine Description Sugarlo-Plus 50/1000 mg
Sugarlo-Plus 50/1000 mg tablets is a medication that combines metformin and vildagliptin, working synergistically to manage blood glucose levels in patients with type 2 diabetes. Metformin primarily acts by reducing hepatic glucose production and enhancing insulin sensitivity in peripheral tissues, leading to improved glucose uptake and utilization. It also has a favorable effect on lipid profiles and may contribute to weight stability or loss. Vildagliptin, on the other hand, is a DPP-4 inhibitor that enhances the levels of incretin hormones, which are responsible for stimulating insulin secretion in response to meals and inhibiting glucagon release. This dual mechanism helps in providing comprehensive glycemic control, particularly in individuals who may not achieve adequate results with metformin alone.
Indications and Uses of Sugarlo-Plus 50/1000 mg tablets
- Management of blood sugar levels in adults with type 2 diabetes mellitus
- Used as an adjunct to diet and exercise to improve glycemic control
- May be recommended for patients who have not achieved adequate control with metformin monotherapy
- Can help in reducing the risk of cardiovascular events in patients with type 2 diabetes
Side Effects of Sugarlo-Plus 50/1000 mg tablets
- Nausea
- Diarrhea
- Stomach pain
- Headache
- Fatigue
- Upper respiratory tract infections
- Hypoglycemia (when used with other antidiabetic medications)
Storage and Handling
Store Sugarlo-Plus 50/1000 mg tablets at room temperature, away from moisture and direct sunlight. Keep out of reach of children.
Patient Advice and Precautions
Patients should adhere to prescribed diet and exercise regimens while on Sugarlo-Plus. Regular monitoring of blood sugar levels is crucial to assess treatment efficacy. It is important to report any unusual symptoms or side effects to a healthcare professional promptly. Avoiding alcohol is recommended as it may increase the risk of lactic acidosis, especially with metformin.